Added to YB: 2026-05-29
Pitch date: 2026-05-27
CCCC [bullish]
C4 Therapeutics, Inc.
-2.92%
current return
Author Info
No bio for this author
Company Info
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Market Cap
$349.3M
Pitch Price
$3.77
Price Target
7.90 (+111%)
Dividend
N/A
EV/EBITDA
-1.54
P/E
-2.95
EV/Sales
4.00
Sector
Biotechnology
Category
growth
C4 Therapeutics: Letting You C What We C
CCCC: Next-gen IKZF1/3 degrader Cemsidomide targets relapsed/refractory multiple myeloma. Ph1: 50% ORR, 9mo mDOR in median 7-line, 75% post-BCMA pts - tougher than BMS's mezigdomide/iberdomide cohorts. 14-on/14-off dosing: 57% Gr3+ neutropenia vs mezi's 71%, zero drug discontinuations. MOMENTUM (4L+, H2'27) + Elrexfio combo (2L+, mid'27) are key catalysts. Base: 10% peak share 4L+/2L+, 50%/33% PoS = $7.90 PT vs $3.80 (~108% upside). ASCO data (May 29) may validate degrader class. Cash to Q1'28.
Read full article (16 min)